Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kami Maddocks

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Experimental Hematology & Oncology|July 13, 2022
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cellsWalter Hanel, Pushpa Lata, Youssef Youssef, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Blood|November 15, 2021
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphomaJeffrey P Ward, Melissa M Berrien-Elliott, Felicia Gomez, et al.
Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.
Blood Advances|January 4, 2018
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinibTracy E Wiczer, Lauren B Levine, Jessica Brumbaugh, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Experimental Hematology & Oncology|July 13, 2022
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cellsWalter Hanel, Pushpa Lata, Youssef Youssef, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Blood|November 15, 2021
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphomaJeffrey P Ward, Melissa M Berrien-Elliott, Felicia Gomez, et al.
Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.
Blood Advances|January 4, 2018
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinibTracy E Wiczer, Lauren B Levine, Jessica Brumbaugh, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Pageof 10